When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...

An AstraZeneca Plc subsidiary is liable for more than $130 million in damages Thursday over its lackluster efforts to ...

Alexion Pharmaceuticals Inc. could later be ordered to pay more in damages for another claim in which Zurn ruled against it, ...

Gefurulimab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Myasthenia Gravis.

LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VYGR), a biotechnology company dedicated to advancing ...

Jab cross. Covid-19 underlined the critical importance of vaccines. The pandemic caused 16 million global deaths, and the ...

Launched by AKF in November 2020, the UCKD Project works to expand access to genetic testing, reduce systemic inequities, engage providers and empower patients. Implementation groups have concentrated ...

Willkie Farr & Gallagher scored a major win at the Third Circuit for bondholders in the bankruptcy of Hertz Corp. entitling ...

Exercise intolerance is often severe among patients with cardiovascular disease and can impose significant limitations on their physical abilities and quality of life. Medications known as cardiac ...

Baker Brothers' 13F portfolio value decreased from $7.97B to $7.83B this quarter. Click here to read more about its fund ...

There are limited treatment options for the large population of patients with heart failure (HF) and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF).  In the FINEARTS-HF trial, finerenone ...

Despite enormous effort, disease-modifying therapies for Alzheimer's disease, the most common cause of dementia, have proven ...